Breast Cancer

A Cue-to-Action Pilot Project to Increase Screening Mammography

February 8th 2021, 5:00pm

Article

A targeted cue-to-action campaign of outreach, education, and incentive can improve uptake of screening mammography.

Mental Illness May Predispose Women With Breast Cancer to Higher Mortality

January 19th 2021, 10:24pm

Article

Severe mental illnesses that precede a breast cancer diagnosis may increase the risk of both all-cause and cancer-specific mortality among women with Medicaid coverage.

Dr Alexey Aleshin Discusses Lingering Struggles in Pinpointing Biomarkers for Breast Cancer Reoccurrence

January 13th 2021, 2:00pm

Video

Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera, said that attention on finding biomarkers for metastatic reoccurrence needs to be directed at women with a high risk of this happening.

Researchers Identify Possible Source of Inflammatory Response Disparity in Black, White Women With Breast Cancer

January 11th 2021, 9:20pm

Article

A more aggressive tumor microenvironment may be to blame for the exaggerated inflammatory response more often seen in Black women with breast cancer compared with White women.

Dr Alexey Aleshin: Persistent ctDNA Is Highly Predictive of Disease Outcome

January 9th 2021, 2:00pm

Video

Changes in circulating tumor DNA (ctDNA) are indicative of treatment response in early-stage breast cancer, pointed out Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.

Risk Factors Identified for Chronic Opioid, Benzodiazepine Use After Mastectomy and Breast Reconstruction

January 4th 2021, 9:02pm

Article

An abstract from last month’s San Antonio Breast Cancer Symposium identifies factors linked with longer-term controlled substance use after treatment of breast cancer with mastectomy plus breast reconstruction in women receiving opioids, benzodiazepines, and other sedative/hypnotics.

Dr Alexey Aleshin: Chemotherapy Is Meant to Eliminate, Reduce Disease Burden

January 1st 2021, 2:00pm

Video

Through neoadjuvant chemotherapy we can downstage tumors, assess drug efficacy, and better segregate women by prognosis status for adjuvant treatment, explained Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.

Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

December 23rd 2020, 10:01pm

Peer-Reviewed

We examine the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.

Supplemental Material: Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

December 23rd 2020, 9:30pm

Peer-Reviewed

Supplemental materials for article examining the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.

Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

December 23rd 2020, 7:00pm

Peer-Reviewed

This article describes treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.